Mississippi House Bill HB865

Mississippi 2026 Regular Session

• Introduced: 1/16/26
• Refer: 1/16/26

Caption

Kratom; add to Schedule III of the Uniform Controlled Substance Act.

Impact

If enacted, this bill will classify kratom as a controlled substance, placing it under rules and regulations governing Schedule III drugs. This amendment would restrict its availability and sale, mimicking regulatory frameworks applied to other substances considered to have potential for abuse and dependency. It will also enhance law enforcement’s ability to address illegal distribution and usage of kratom, thereby potentially reducing its incidence in the state.

Summary

House Bill 865 proposes to amend the Mississippi Code to include kratom in Schedule III of the Uniform Controlled Substances Act. This change reflects a growing recognition of the potential risks associated with kratom, which is a substance derived from the leaves of the Mitragyna speciosa tree. Supporters of the bill emphasize the need for regulation due to concerns about its misuse and the health risks it may pose to consumers. By placing kratom in a controlled substance schedule, the state seeks to limit access to the substance in order to protect public health.

Sentiment

The sentiment surrounding HB 865 is mixed. Advocates argue that regulating kratom will prevent its misuse, particularly in populations susceptible to addiction. They cite anecdotal evidence and growing concerns amongst health professionals regarding kratom's safety. On the other hand, opponents of the legislation suggest that kratom has therapeutic benefits and that criminalizing it may negatively impact those who use it as a safer alternative to prescription opioids. This division in sentiment indicates a broader debate about drug control policy's effectiveness and morality.

Contention

Notable points of contention include the lack of comprehensive scientific research regarding kratom’s long-term effects and its potential benefits as a pain management tool. While proponents of the bill focus on the substance's risks, opponents highlight the potential therapeutic uses that may be interrupted by its scheduling. This disconnect raises questions about the balance between public health safety and personal autonomy, as well as the appropriateness of legislative action in areas where scientific consensus is still emerging.